The absorption, distribution, metabolism, excretion, and pharmacokinetic properties of the pan-rapidly accelerated fibrosarcoma (RAF) inhibitor naporafenib in healthy subjects: An absolute bioavailability and mass balance study.

naporafenib (ERAS-254) - Erasca

http://www.ncbi.nlm.nih.gov/pubmed/42759207

Ai Ling Ching; Alfin Vaz; Dawei Xuan; Justine L Lam; Roxana Picard; Shinji Fujimori; Xiaoying Chen; Zhongzhou Shen

Sep 19, 2026